Certara, Inc.

Certara, Inc. builds biosimulation software and technology-enabled consulting services used in drug discovery and development. The company’s tools help biopharmaceutical teams apply model-informed drug development (MIDD) to predict outcomes, reduce development risk, and support regulatory submissions. Its platform is used across the life sciences value chain, from early research through clinical development and regulatory review. Certara also sells software to global drug regulators and provides project-based scientific services delivered by experienced drug-development specialists. The business is anchored in the adoption of quantitative modeling in life sciences rather than in traditional enterprise software workflows.

23,0 %

−0,4 %

+8,7 %

2.05

2.05

— Certara, Inc.
%
Software licenses30% Perpetual or term licenses for validated biosimulation applications delivered upfront.
Software subscriptions35% Cloud-based access and support for Certara software recognized ratably over the contract term.
Maintenance and support10% Ongoing support, updates, and maintenance tied to installed software and subscriptions.
Consulting and technology-enabled services25% Scientist-led project work that applies biosimulation and MIDD to customer programs.

Certara sells primarily to biopharmaceutical and biotech companies that use its software and services to improve R&D...

  • Biopharmaceutical companiesprimary

    Buy biosimulation software and consulting to improve R&D productivity, support filings, and reduce development risk.

  • Biotech companiesprimary

    Use the platform for model-informed development with limited internal resources and high pipeline uncertainty.

  • Contract research organizationssecondary

    Purchase software and services to execute modeling and simulation work on behalf of sponsor clients.

  • Regulators and government agenciessecondary

    License software for scientific review, assessment, and decision support in drug regulation.

  • Academic and public sector institutionssecondary

    Use the tools for research, training, and translational science applications.

  • Adjacent life sciences industriesemerging

    Buy selected software and services for animal health, crop science, bio science, and medical devices.

Certara operates globally and says its solutions have been used by customers in more than 70 countries...

  • •Global customer base across more than 70 countries
  • •Strong exposure to the United States through FDA-related use cases
  • •European presence through EMA and UK MHRA regulatory adoption
  • •Asia exposure through Japan PMDA and China CDE usage
  • •International expansion supported by direct sales and distributors
  • •No country-level revenue split disclosed in the excerpts

Certara’s strategy is to expand the breadth and depth of its biosimulation platform across the drug-development...

01
Broaden the platform with new software and servicesmedium-term

A wider product set increases wallet share and makes Certara more embedded in customer workflows.

02
Expand international commercial reachmedium-term

Growth depends on adoption across more geographies and regulatory systems.

03
Drive regulatory and scientific acceptance of MIDDlong-term

Regulatory support is a key demand driver for biosimulation in drug development.

04
Pursue acquisitions and complementary businessesmedium-term

Acquisitions can add capabilities, customers, and cross-sell opportunities.

Certara’s demand depends on continued acceptance of model-informed drug development by regulators, academic...

high

Slow acceptance of model-informed biopharmaceutical development

Demand for Certara’s software and services depends on regulators and customers continuing to embrace biosimulation and MIDD.

Scope
Core demand driver
Materiality
high
high

Customer consolidation in biopharma

Mergers can reduce the number of licenses and users, and merged companies may negotiate lower prices.

Scope
Large pharma customer base
Materiality
high
high

Cybersecurity and service disruption

The company relies on software applications and IT systems that could be affected by cyberattacks, outages, or failures.

Scope
Cloud/software operations
Materiality
high
medium

Compliance with anti-bribery and public-sector rules

Sales to regulators and foreign government-related entities increase exposure to FCPA, Bribery Act, and procurement compliance.

Scope
Government and international sales
Materiality
medium
Revenue recognition for licenses, subscriptions, maintenance, and services
Important for quarterly comparability and backlog interpretation
Seasonality and renewal timing
Affects quarterly run-rate analysis
Organic revenue and acquisition adjustments
Important for assessing core operating momentum
Valuation allowance and tax estimates
Can create volatility in reported earnings

Simulations Plus, Inc.

SLP · Services-Computer Integrated Systems Design

Fortrea Holdings Inc.

FTRE · Services-Medical Laboratories

AbCellera Biologics Inc.

ABCL · Pharmaceutical Preparations

Azitra, Inc.

AZTR · Pharmaceutical Preparations

LISATA THERAPEUTICS, INC.

LSTA · Pharmaceutical Preparations

SECTRA

SECT-B.ST · Health Care

: 28/04/2026